Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Novartis's Batoprotafib?
Batoprotafib is a small molecule commercialized by Novartis, with a leading Phase II program in Non-Small Cell Lung Cancer. According...
Data Insights
Risk adjusted net present value: What is the current valuation of Novartis's Batoprotafib?
Batoprotafib is a small molecule commercialized by Novartis, with a leading Phase II program in Solid Tumor. According to Globaldata,...